文献速递头颈部肿瘤放疗

老年局部晚期鼻咽癌:标准化同步放化疗是否仍为首选?

Should standard concurrent chemoradiotherapy remain the preferred treatment for elderly patients with locoregionally advanced nasopharyngeal carcinoma?
PubMed 文献 · Radiat Oncol · 2026-05-09

本研究回顾性分析中国两中心393例≥65岁局部晚期鼻咽癌患者,经倾向性评分匹配后比较标准化疗(铂类同步放化疗)与个体化治疗的疗效与安全性。匹配队列中两组生存结局无显著差异,但个体化治疗组≥3级血液学毒性显著更低;探索性分层提示单纯放疗生存较差,放疗联合全身治疗生存与标准治疗相似。

要点

  • 老年局晚鼻咽癌标准同步放化疗与个体化治疗生存无显著差异
  • 个体化治疗≥3级白细胞减少和中性粒细胞减少显著低于标准治疗
  • 探索性分析提示放疗联合全身治疗可能是更优个体化选择

核心结论

  • 在老年局部晚期鼻咽癌患者中,标准同步放化疗与个体化治疗相比未改善生存结局,而个体化治疗安全性更好。
  • 探索性分层分析提示,放疗联合全身治疗可能是更有前景的个体化治疗选择。

研究设计与样本

  • 回顾性分析中国两个中心2013年1月至2020年12月收治的393例≥65岁局部晚期鼻咽癌患者。
  • 按治疗分为标准治疗组(铂类同步放化疗,可联合诱导/辅助治疗)和个体化治疗组(单纯放疗或同步放疗联合非化疗药物,可联合诱导/辅助治疗)。
  • 采用倾向性评分匹配生成141对患者,用Kaplan-Meier法和Cox比例风险模型分析生存,用卡方或Fisher精确检验比较毒性。

主要发现

  • 在倾向性评分匹配队列中,标准治疗组与个体化治疗组的总生存、肿瘤特异性生存、无进展生存、局部区域无复发生存和远处无转移生存均无显著差异(均P > 0.05)。
  • 多因素分析证实治疗组(标准治疗 vs 个体化治疗)不是任何生存终点的显著预测因素。
  • 探索性分层分析中,单纯放疗与较差的总生存、肿瘤特异性生存和无进展生存相关,而放疗联合全身治疗的生存结局与标准治疗相似。
  • 与标准治疗组相比,个体化治疗组≥3级血液学毒性显著更低,包括白细胞减少(8.5% vs 23.4%;P = 0.001)和中性粒细胞减少(12.3% vs 20.6%;P = 0.013)。

关键数值与推荐

  • 倾向性评分匹配队列141对,标准治疗与个体化治疗各项生存终点比较均P > 0.05。
  • ≥3级白细胞减少:个体化治疗组8.5% vs 标准治疗组23.4%(P = 0.001)。
  • ≥3级中性粒细胞减少:个体化治疗组12.3% vs 标准治疗组20.6%(P = 0.013)。

临床怎么用

  • 对≥65岁局部晚期鼻咽癌患者,标准同步放化疗未显示生存优势且血液学毒性更高,个体化治疗可作为合理选择。
  • 若选择个体化治疗,探索性结果提示应优先考虑放疗联合全身治疗而非单纯放疗。

局限性

  • 本研究为回顾性分析,存在选择偏倚等回顾性研究固有局限。
  • 探索性分层分析结果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elderly patients are underrepresented in clinical studies supporting platinum-based concurrent chemoradiotherapy (CCRT) as the standard therapy (ST) for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Many such patients in real-world settings cannot tolerate CCRT and instead receive individualized therapy (IT). This study aimed to compare the efficacy and safety of ST versus IT in elderly NPC patients. METHODS: A retrospective analysis was conducted on 393 elderly (≥ 65 years) LA-NPC patients from two centers in China between January 2013 and December 2020. Patients were categorized into ST (platinum-based CCRT with or without induction/adjuvant therapy) or IT (radiotherapy alone, or concurrent radiotherapy with non-chemotherapy agents, with or without induction/adjuvant therapy) groups. Propensity score matching (PSM) generated 141 patient pairs. Survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazards models. Toxicities were compared with chi-square or Fisher's exact tests. RESULTS: In the PSM cohort, no significant differences were observed between the ST and IT groups in overall survival, cancer-specific survival, progression-free survival, locoregional relapse-free survival, and distant metastasis-free survival (all P > 0.05). Multivariable analysis confirmed that treatment group (ST vs. IT) was not a significant predictor for any survival endpoint. In exploratory stratified analysis, radiotherapy alone was associated with inferior OS, CSS, and PFS, whereas radiotherapy combined with systemic therapy showed survival outcomes similar to those of ST. Additionally, compared with the ST group, the IT group had significantly lower rates of grade 3 or higher hematologic toxicities, including leukopenia (8.5% vs. 23.4%; P = 0.001) and neutropenia (12.3% vs. 20.6%; P = 0.013). CONCLUSION: Standard CCRT was not associated with improved survival outcomes compared with individualized therapy in elderly patients with LA-NPC, while individualized therapy showed a more favorable safety profile. Exploratory stratified analysis further suggested that radiotherapy combined with systemic therapy may represent a more promising individualized therapy option. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao S, Zhang J, Zhu Y, et al. Should standard concurrent chemoradiotherapy remain the preferred treatment for elderly patients with locoregionally advanced nasopharyngeal carcinoma? Radiat Oncol. 2026. PMID: 42106762. doi:10.1186/s13014-026-02850-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。